Innate Pharma
IPHA
9 hedge funds and large institutions have $731K invested in Innate Pharma in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
49% more capital invested
Capital invested by funds: $491K → $731K (+$241K)
13% more funds holding
Funds holding: 8 → 9 (+1)
0.1% more ownership
Funds ownership: 0.22% → 0.31% (+0.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ETC
Exchange Traded Concepts
Oklahoma City,
Oklahoma
|
+$173K |
| 2 |
Optiver Holding
Amsterdam,
Netherlands
|
+$125K |
| 3 |
Jane Street
New York
|
+$38.1K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$168 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$127K |
| 2 |
Millennium Management
New York
|
-$3.73K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ETC
1
Exchange Traded Concepts
Oklahoma City,
Oklahoma
| $326K | +$173K | +66,182 | +141% |
|
|
2
Optiver Holding
Amsterdam,
Netherlands
| $203K | +$125K | +47,859 | +211% |
|
|
3
Morgan Stanley
New York
| $127K | -$127K | -48,584 | -52% |
|
|
4
Jane Street
New York
| $41.9K | +$38.1K | +14,554 | New |
|
|
5
Millennium Management
New York
| $30.5K | -$3.73K | -1,423 | -12% |
|
6
Barclays
London,
United Kingdom
| $1.19K | – | – | – |
|
|
7
UBS Group
Zurich,
Switzerland
| $604 | +$168 | +64 | +44% |
|
8
RhumbLine Advisers
Boston,
Massachusetts
| $590 | – | – | – |
|
|
SPIA
9
Steward Partners Investment Advisory
New York
| $576 | – | – | – |
|
IPHA Hedge Fund Activity: Q1 2024 in Review
9 of the 6,945 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q1 2024, worth a combined $731K — up 49% from $491K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new IPHA positions and 0 closed out — a net gain of 1 holder — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Exchange Traded Concepts, adding an estimated $173K. The largest seller was Morgan Stanley, cutting an estimated $127K.
- 9 institutional investors held Innate Pharma (IPHA) as of Q1 2024, up from 8 in Q4 2023.
- Funds reported $731K of Innate Pharma stock for Q1 2024, up 49% quarter-over-quarter.
- 1 fund opened new Innate Pharma positions in Q1 2024 and 0 closed out, a net change of +1 holder.
- The largest Innate Pharma buyer in Q1 2024 was Exchange Traded Concepts, an estimated $173K added.
- The largest Innate Pharma seller in Q1 2024 was Morgan Stanley, an estimated $127K sold.
Based on aggregated 13F filings for Q1 2024.